E - Glenmark

More documents

Recommendations

Info

India Formulations Current Status: FY 2006 Revenue growth of 30% over FY 2005, 39% growth in March 2006 [ORG- IMS] Ranked #2 in dermatology (after GSK), strong presence in over 10 segments including female healthcare, paediatrics, respiratory, antiinfectives, cardiovascular, diabetology Increased focus on chronic lifestyle diseases Launched 45 new products and novel combinations including 15 first generics such as Strontium Ranelate, Diacerin, Eplerenone, Acitretin, S- ibuprofen Created 7 retail divisions, 1 institutional division for improved focus Grew field force (currently 1700 medical representatives) and increased focus on productivity improvements Driving supply chain cost down; new plant at Baddi for tax-efficiencies Commenced in-licensing and co-marketing tie-ups for novel products
India Formulations Segment Contribution to Revenue: Diversified across therapies Segment Contribution ORG MAT Mar 2005 Alimentary T. & Metabolism Blood + B. Forming Organs Segment Contribution ORG MAT Mar 2006 15% 3% 15% 1% 13% 5% 12% 4% 32% Cardiovascular System Dermatologicals G. U. System & Sex Hormones Systemic Anti- Infectives 7% 14% 17% 4% 3% 16% 32% 1% Musculo-Skeletal System Respiratory System Sensory Organs 6%
Page 2 and 3: Disclaimer This presentation has be
Page 4 and 5: Background History Identity / Scope
Page 6 and 7: Strategic roadmap: Transform into a
Page 8 and 9: Build proprietary pipeline of NCEs/
Page 10 and 11: NCE Research & Development Plan to
Page 12 and 13: NCE Pipeline Lead Target Indication
Page 14 and 15: Biologics research in Switzerland i
Page 16 and 17: Overview: Build/consolidate “bran
Page 20 and 21: India Formulations Moving forward,
Page 22 and 23: Latin America Status in FY 2006 Ac
Page 24 and 25: USA - Generic Formulations Progress
Page 26 and 27: Europe / UK - Start-up phase Strate
Page 28 and 29: Active Pharmaceutical Ingredients S
Page 30 and 31: Financials and Projections Performa
Page 32 and 33: Summary
Page 34: Thank you

E - Glenmark

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?